Stem cells are expected to revolutionize the treatment of today's severe and incurable diseases. NextCell develops pioneering stem cell therapies for the treatment of autoimmune and inflammatory diseases as well as for use in organ transplants.
Technology
NextCell develops ProTrans™, a drug candidate consisting of stem cells for the treatment of autoimmune diseases, initially focusing on type- 1 diabetes. ProTrans is based on NextCell patent pending Selection Algorithm. Further, NextCell runs Cellaviva, Nordic's largest private stem cell bank, approved by IVO.
NextCell Pharma AB ("NextCell") today announces that the ProTrans-2 clinical trial met the primary endpoint. Patients treated with a single dose ProTrans show a statistically significant improved preservation of insulin production over 12 months, compared to patients treated with placebo (p-value < 0.05).
NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from umbilical cord. NextCell is focusing on research and development of novel stem cell therapies and is also running a tissue establishment and primary biobank, classified as healthcare provider.
NextCell is listed on the Nasdaq First North Growth Market. Here you will find information about the share, the latest reports and other financial data.
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 2 for the period September 1, 2021 – February 28, 2022 The report is available on the company’s website:
https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth M
NextCell is attending a conference for worldleading celltherapies
NextCell Pharma AB ("NextCell" or the"Company") is attending the International Society for Cell and Gene Therapy 2022 in San Francisco, May 4-7. The company is represented by Mathias Svahn, CEO who is a member of the Business Development and Finance Committee will participate in workshops, round t
First age group treated in paediatric diabetes study with ProTrans
NextCell Pharma AB ("NextCell") today announces that all three children in the age group 12-18 years have been treated with ProTrans. Professor Per-Ola Carlsson and the study team are now moving forward with younger patients, three children in the age group 7-11 years.
Cellaviva delivers stem cells to treat serious blood disease
NextCell Pharma AB ("NextCell" or the ”Company”) announces that the stem cell bank Cellaviva has released umbilical cord blood stem cells to Rigshospitalet, Denmark's leading hospital.